Interpatient heterogeneity was characterized within HR-negative HER2-low breast cancers by identifying two distinct subgroups, and we found that the distinctness of HER2-low breast cancers might result from the enrichment of the distinct non-basal-like tumors. This evidence concerns the gene ERBB2 and breast cancer.